Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Eli Lilly and Company
Condition: Adenocarcinoma of the Prostate
NCT00520481
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.